Seeking Alpha
13 Sept 2026, 10:10 UTC · 7h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
2 claims · each scored for market impact
Kardigan's lead programs for genetic DCM, moderate CAVS, and post-hospitalization ASH will yield pivotal data in 2027. — Binary clinical trial outcomes for multiple lead programs are the primary drivers of valuation for biotech firms.
+0.60Kardigan holds $660.7M in liquid assets, providing a cash runway of approximately 2–3 years. — Strong liquidity reduces immediate dilution risk and ensures the company can reach its next major value-inflection points.
+0.40Which stocks this story touches
The company has a strong cash position with 2-3 years of runway and clear clinical catalysts.
Continue reading
5 related stories
Search tags
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
MarketBeat
3h ago
